Literature DB >> 10742969

Meta-analysis: methods, strengths, and weaknesses.

M Buyse1, P Piedbois, Y Piedbois, R W Carlson.   

Abstract

Meta-analysis is a systematic, quantitative approach to the combination of data from several clinical trials that address the same question. This analytic approach can help resolve questions that remain unclear from the results of individual trials. Meta-analysis is of particular interest in oncology because of the small differences in efficacy between therapeutic alternatives. The large number of patients included in meta-analyses permit small to moderate benefits of a treatment to be reliably detected and larger treatment benefits to be quantified more accurately. Despite these apparent benefits, the use of meta-analysis has met with a great deal of resistance and has generated much controversy in clinical journals. After a brief description of the basic methods of conducting meta-analyses, this article will explore both their advantages and disadvantages.

Entities:  

Mesh:

Year:  2000        PMID: 10742969

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  5 in total

1.  Implementation and limitations of meta-analysis of randomized trials from the clinical biostatistician's point of view.

Authors:  Junichi Sakamoto
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

Review 2.  Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer.

Authors:  Marc Buyse
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

Review 3.  Quality of Meta-Analyses for Randomized Trials in the Field of Hypertension: an Updated and Improved Systematic Review.

Authors:  George C Roush; Fiorella Perez; Ramy Abdelfattah; Andrew Prindle; Elie Jean; Tanveer Singh; John B Kostis; William J Kostis; William J Elliott; Jesse A Berlin
Journal:  Curr Hypertens Rep       Date:  2017-09       Impact factor: 5.369

Review 4.  Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis.

Authors:  Justin M Belcher; Steven G Coca; Chirag R Parikh
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

5.  Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study.

Authors:  Béranger Lueza; Audrey Mauguen; Jean-Pierre Pignon; Oliver Rivero-Arias; Julia Bonastre
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.